I am a postdoctoral fellow in the lab of Arnold Kriegstein at the University of California, San Francisco (UCSF). I focus on applying single-cell genomics techniques to study the development of specific cell types of the human brain, as well as to understand how these cell types are affected in various diseases, especially autism. Before starting my work at UCSF, I did my PhD at the University of Miami focusing on genomic analysis of autism. I did my B.S. and MS at Moscow State University in my native Russia, where I worked on animal models of epilepsy and Alzheimer’s disease.
Dmitry Velmeshev
Postdoctoral Scholar
University of California, San Francisco
From this contributor
Single-cell analysis suggests brain signaling problems in autism
Recent advances in technology allow researchers to measure RNA that is contained within the nucleus of a single brain cell.
Single-cell analysis suggests brain signaling problems in autism
Explore more from The Transmitter
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
‘Tour de force’ study flags fount of interneurons in human brain
The newly discovered cell type might point to the origins of the inhibitory imbalance linked to autism and other conditions.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”